Multiple Myeloma (Kahler Disease) (Oncology) – Drugs in Development, 2021

Global Markets Direct’s, ‘Multiple Myeloma (Kahler Disease) – Drugs In Development, 2021’, provides an overview of the Multiple Myeloma (Kahler Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease)

– The report reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Multiple Myeloma (Kahler Disease) therapeutics and enlists all their major and minor projects

– The report assesses Multiple Myeloma (Kahler Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler Disease)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

A. Menarini Industrie Farmaceutiche Riunite Srl

Aadi Bioscience Inc

Abbisko Therapeutics Co Ltd

AbbVie Inc

Abcuro Inc

ABL Bio Inc

Actinium Pharmaceuticals Inc

Active Biotech AB

Adicet Bio Inc

Aeglea BioTherapeutics Inc

Affimed GmbH

AGC Biologics SpA

Allife Medical Science and Technology Co Ltd

Allogene Therapeutics Inc

Alphamab Oncology

Ambrx Biopharma Inc

Amgen Inc

Anaveon AG

Antaimmu BioMed Co Ltd

Antengene Corp Ltd

Antion Biosciences SA

APIM Therapeutics AS

APO-T BV

Arcellx Inc

Arch Oncology Inc

Arcus Biosciences Inc

Ariz Precision Medicine Inc

Arjuna Therapeutics

Arovella Therapeutics Ltd

Ascenta Therapeutics Inc

Ascentage Pharma Group International

Asclepius Technology Company Group Suzhou Co Ltd

Aslan Pharmaceuticals Ltd

AstraZeneca Plc

Asylia Therapeutics Inc

Auransa Inc

Aurigene Discovery Technologies Ltd

Autolus Therapeutics Plc

Avalo Therapeutics Inc

Ayala Pharmaceuticals Inc

Bantam Pharmaceutical LLC

Bayer AG

BeiGene Ltd

Beijing Immunochina Pharmaceuticals Co Ltd

Beijing Menlo Biotechnology Co Ltd

Beijing Sunbio Biotech Co Ltd

Bellicum Pharmaceuticals Inc

Betta Pharmaceuticals Co Ltd

BeyondSpring Inc

Biocad

BioCurate Pty Ltd

BioLineRx Ltd

Biomea Fusion Inc

Biosion Inc

BioVec Pharma Inc

BioVie Inc

Bivictrix Therapeutics PLC

bluebird bio Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

C4 Therapeutics Inc

Calithera Biosciences Inc

CanBas Co Ltd

Cantex Pharmaceuticals Inc

Carbiogene Therapeutics Co Ltd

Caribou Biosciences Inc

CARsgen Therapeutics Ltd

Cartesian Therapeutics Inc

CASI Pharmaceuticals Inc

CDR-Life Inc

Cell Source Inc

CellCentric Ltd

Cellectar Biosciences Inc

Cellectis SA

Celleron Therapeutics Ltd

Cellestia Biotech AG

Cello Therapeutics Inc

Cellular Biomedicine Group Inc

Celularity Inc

Celyad Oncology SA

Centrax International Inc

Ceptur Therapeutics Inc

Checkpoint Therapeutics Inc

Cheetah Cell Therapeutics Co Ltd

Chia Tai Tianqing Pharmaceutical Group Co Ltd

Chimerix Inc

China Immunotech (Beijing) Biotechnology Co Ltd

Chinook Therapeutics Inc

Chong Kun Dang Pharmaceutical Corp

Chongqing Precision Biotech Co Ltd

CiMaas BV

Cleave Therapeutics Inc

Compugen Ltd

Convalife

Corvus Pharmaceuticals Inc

CRISPR Therapeutics AG

CSPC Pharmaceutical Group Ltd

CStone Pharmaceuticals Co Ltd

Curocell Inc

Cyclacel Pharmaceuticals Inc

Cyteir Therapeutics Inc

Cytovia Therapeutics Inc

Daiichi Sankyo Co Ltd

DeuteRx LLC

DexTech Medical AB

Diverse Biotech Inc

Eli Lilly and Co

Elpis Biopharmaceuticals Corp

EpicentRx Inc

EpimAb Biotherapeutics Inc

Epizyme Inc

Eternity Bioscience Inc

eTheRNA Immunotherapies NV

Eureka Therapeutics Inc

EUSA Pharma (UK) Ltd

ExCellThera Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Fera Pharmaceuticals LLC

Fortis Therapeutics Inc

Fusion Pharmaceuticals Inc

Gadeta BV

Galileo Research srl

Gamida Cell Ltd

GEMoaB Monoclonals GmbH

GemoPharm

Genenta Science srl

Genentech USA Inc

Genmab AS

Geron Corp

Gilead Sciences Inc

GlaxoSmithKline Plc

Gliknik Inc

GlycoMimetics Inc

Glycostem Therapeutics BV

GlyTR Therapeutics Inc

GP Pharm SA

Gracell Biotechnologies Inc

GT Biopharma Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

Guangzhou Bio-gene Technology Co Ltd

HaemaLogix Pty Ltd

Hangzhou DAC Biotech Co Ltd

Hangzhou Sumgen Biotech Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

Harbour BioMed (Guangzhou) Co Ltd

Harpoon Therapeutics Inc

Hebei Senlang Biotechnology Co Ltd

Heidelberg Pharma AG

Helix BioPharma Corp

Helocyte Biosciences Inc

Hengenix Biotech Inc

Hinova Pharmaceuticals Co Ltd

HitGen Inc

Holy Stone Healthcare Co Ltd

HRAIN Biotechnology Co Ltd

Hummingbird Bioscience Pte Ltd

Hunan Siweikang Therapeutics Ltd

HuniLife Biotechnology Inc

Hutchison MediPharma Ltd

I-Mab

iCell Gene Therapeutics LLC

Ichnos Sciences Inc

IDAC Theranostics Inc

IDP Discovery Pharma SL

IGM Biosciences Inc

Immix BioPharma Inc

ImmuneCyte Inc

ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

ImmuneTarget Inc

Immunicum AB

ImmunityBio Inc

Immunotech Biopharm Ltd

Immunwork Inc

Incyte Corp

Indapta Therapeutics Inc

Inflection Biosciences Ltd

Inmune Bio Inc

InnoCare Pharma Ltd

Innovative Cellular Therapeutics Co Ltd

Intra-Immusg Pvt Ltd

Inventiva SA

IO Biotech Inc

Io Therapeutics Inc

Ionis Pharmaceuticals Inc

Ionova Life Science Co Ltd

Istesso Ltd

iTeos Therapeutics Inc

Iterion Therapeutics Inc

Jiangsu Carephar Pharmaceutical Co Ltd

Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Zhengda Fenghai Pharmaceutical Co Ltd

Jiangxi Shanxing Biotechnology Co Ltd

JN Biosciences LLC

Johnson & Johnson

JSK Therapeutics Inc

Jubilant Therapeutics Inc

Juventas Cell Therapy Ltd

JW Pharmaceutical Corp

K36 Therapeutics Inc

Kangpu Biopharmaceuticals Ltd

Karyopharm Therapeutics Inc

KeyMed Biosciences Inc

Kiadis Pharma NV

KisoJi Biotechnology Inc

Klyss Biotech Inc

Kodikaz Therapeutic Solutions Inc

Komipharm International Co Ltd

Kronos Bio Inc

KYAN Therapeutics Inc

Kymab Ltd

Laekna Therapeutics Shanghai Co Ltd

LAVA Therapeutics NV

Leadiant Biosciences Inc

Legend Biotech Corp

Les Laboratoires Servier SAS

Leukogene Therapeutics Inc

Ligand Pharmaceuticals Inc

LintonPharm Co Ltd

Lokon Pharma AB

Loxo Oncology Inc

Luminus Biosciences Inc

Luye Pharma Group Ltd

Mablink Bioscience

Machavert Pharmaceuticals LLC

Marker Therapeutics Inc

Max Biopharma Inc

MediGene AG

MedPacto Inc

Merck & Co Inc

Millennium Pharmaceuticals Inc

Miltenyi Biotec BV & Co KG

MimiVax LLC

MiNK Therapeutics Inc

Modulation Therapeutics Inc

Molecular Partners AG

Molecular Templates Inc

Morphogenesis Inc

MorphoSys AG

Multitude therapeutics Inc

Mustang Bio Inc

Mycovia Pharmaceuticals Inc

Nanexa AB

Nanjing Aimeifei Biomedical Technology Co Ltd

Nanjing Bioheng Biotech Co Ltd

Nanjing Iaso Biotherapeutics Co Ltd

Nektar Therapeutics

Neoleukin Therapeutics Inc

Neomics Pharmaceuticals LLC

Neonc Technologies Inc

Nerviano Medical Sciences SRL

Newave Pharmaceutical Inc

NewBay Medical Technology Co Ltd

NexImmune Inc

Northlake International LLC

Novartis AG

Oncodesign SA

OncoFusion Therapeutics Inc

Oncolytics Biotech Inc

OncoMyx Therapeutics Inc

Onconova Therapeutics Inc

OncoPep Inc

Oncopeptides AB

OncoTartis Inc

OncoTherapy Science Inc

One World Cannabis Ltd

ONK Therapeutics Ltd

Ono Pharmaceutical Co Ltd

Onward Therapeutics SA

Orgenesis Inc

ORIC Pharmaceuticals Inc

Origincell Technology Group Co Ltd

Otsuka Pharmaceutical Co Ltd

Paras Biopharmaceuticals Finland Oy

PentixaPharm GmbH

PersonGen Anke Cellular Therapeutics Co Ltd

PersonGen Biomedicine Suzhou Co Ltd

Pfizer Inc

Pharma Mar SA

Phi Pharma SA

Phosplatin Therapeutics LLC

PI Therapeutics Ltd

Pimera Inc

Pinotbio Inc

Poseida Therapeutics Inc

Precision Biosciences Inc

Pregene ShenZhen Biotechnology Co Ltd

Prelude Therapeutics Inc

Prescient Therapeutics Ltd

Protheragen Inc

Qilu Pharmaceutical Co Ltd

Quadriga BioSciences Inc

Qwixel Therapeutics LLC

Rapa Therapeutics LLC

RAPT Therapeutics Inc

Raqia Therapeutics Inc

Regeneron Pharmaceuticals Inc

RESTEM

SA Science Inc

Sana Biotechnology Inc

Sanofi

Seagen Inc

SELLAS Life Sciences Group Inc

Senhwa Biosciences Inc

Shandong New Time Pharmaceutical Co Ltd

Shanghai Biomed-Union Biotechnology Co Ltd

Shanghai Bioray Laboratory Inc

Shanghai GeneChem Co Ltd

Shanghai Junshi Bioscience Co Ltd

Shanghai Keqi Pharmaceutical Technology Co Ltd

Shanghai Novamab Biopharmaceuticals Co Ltd

Shanghai Theorion Pharmaceutical Co Ltd

Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd

Shanghai YaKe Biotechnology Co Ltd

Shanghai Yingli Pharmaceutical Co Ltd

Shenogen Pharma Group Ltd

Shenzhen Chipscreen Biosciences Co Ltd

Shenzhen Neptunus Institute of Pharmaceutical Technology Co Ltd

Shenzhen Targetrx Inc

Shuttle Pharmaceuticals Inc

Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd

Sichuan Kelun Pharmaceutical Co Ltd

SignalRx Pharmaceuticals Inc

SignPath Pharma Inc

Sorrento Therapeutics Inc

SpecificiT Pharma Inc

Sphaera Pharma Pte Ltd

SpringWorks Therapeutics Inc

Starton Therapeutics Inc

Sumitomo Dainippon Pharma Oncology, Inc

Sunnycell Therapeutics Ltd

Sunomix Therapeutics

Surface Oncology Inc

Sutro Biopharma Inc

Suzhou Maximum Bio-tech Co Ltd

Synactix Pharmaceuticals Inc

SynDevRx Inc

T-Cure Bioscience Inc

T-CURX GmbH

Taiho Oncology Inc

TaiRx Inc

Takeda Pharmaceutical Co Ltd

Targazyme Inc

Telix Pharmaceuticals Ltd

Tianweiyuan and Biomedicine Shanghai Co Ltd

TiCARos Co Ltd

Tiziana Life Sciences Plc

Tmunity Therapeutics Inc

Transgene Biotek Ltd

Triterpenoid Therapeutics Inc

Triumvira Immunologics Inc

TSD Life Sciences

TTY Biopharm Co Ltd

Ube Industries Ltd

Up Therapeutics Inc

VaxcellBio Inc

Vaxil Bio Therapeutics Ltd

Verastem Inc

Vichem Chemie Research Ltd

Vincerx Pharma Inc

Visterra Inc

Vycellix Inc

Vyriad Inc

Wellington Zhaotai Therapies Ltd

Wigen Biomedicine Technology (Shanghai) Co Ltd

WindMIL Therapeutics Inc

Wugen Inc

Wuhan Bio-Raid Biotechnology Co Ltd

Wuhan YZY Biopharma Co Ltd

XBiotech Inc

XEME BioPharma Inc

Xencor Inc

Xi'An Yufan Biotechnology Co Ltd

Xiangxue Life Sciences

XNK Therapeutics AB

Zhengda Tianqing Pharmaceutical Group Co Ltd

Zovis Pharmaceuticals

Zymergen Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Multiple Myeloma (Kahler Disease) - Overview

Multiple Myeloma (Kahler Disease) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Multiple Myeloma (Kahler Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development

Multiple Myeloma (Kahler Disease) - Drug Profiles

Multiple Myeloma (Kahler Disease) - Dormant Projects

Multiple Myeloma (Kahler Disease) - Discontinued Products

Multiple Myeloma (Kahler Disease) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodol'ogy

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Multiple Myeloma (Kahler Disease), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Multiple Myeloma (Kahler Disease) – Dormant Projects, 2021

Multiple Myeloma (Kahler Disease) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Multiple Myeloma (Kahler Disease), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports